timothy sykes logo

Stock News

INmune Bio’s Future: Buying, Holding, or Selling?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 8/4/2025, 9:19 am ET 8/4/2025, 9:19 am ET | 6 min 6 min read
INmune Bio’s Future: Buying, Holding, or Selling? Thumbnail

INmune Bio Inc.’s stocks have been trading up by 13.68 percent following significant investor optimism reflected in recent news.

Candlestick Chart

Live Update At 09:18:40 EST: On Monday, August 04, 2025 INmune Bio Inc. stock [NASDAQ: INMB] is trending up by 13.68%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Earnings Overview and Financial Metrics

Trading can often be a rollercoaster ride of highs and lows, making it essential to master the art of managing what we earn. It’s not just about securing substantial profits in the short term; rather, the true success in trading lies in the discipline of retaining those profits. As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This principle highlights the importance of strategies such as cutting losses quickly, diversifying trades, and having a strong risk management plan. Successful traders understand that maintaining and growing their trading capital over time is what truly determines long-term success in the market.

In recent times, INmune Bio has been the talk among investors, especially after their March quarter financial results. Total revenue was a meager $50,000, while operating expenses ballooned to $9.96M, primarily driven by research costs. Interestingly, despite facing substantial losses, the gross margin remained strong at 100%, suggesting that overheads were the primary source of the dent, rather than production costs.

A deep dive into key financial metrics shows some conflicting narratives. The firm showcases a sky-high price-to-sales ratio, suggesting overvaluation to some analysts. Nevertheless, a stable current ratio of 2.6 indicates INmune Bio’s ability to meet short-term obligations without batting an eye. Both quick and leverage ratios stand firm at 2.6 and 1.3 respectively, underscoring some underlying financial solidity amid rough patches.

Their assets, primarily the cash reserves at $19.33M, appear robust in the face of adversity. Yet, a glance at profitability metrics tells a less than rosy story. Enhanced return on assets and equity numbers offer a cautionary tale about the company’s efficiency in generating returns, portraying a negative image often linked to aggressive startup growth phases.

The lack of dividends only amplifies the company’s current reinvestment stance. Thus, INmune Bio stands at an uncertain juncture where only time will tell if their bullish endeavors, especially in Alzheimer’s research, smartly pay off.

R&D Results and Implications

The unveiled video presentation anticipated at the AAIC, Toronto, represents a crucial tile in this vast research endeavor mosaic. There are whispers of doubts concerning the trial not achieving its primary objectives; yet, piecemeal wins in particular patient classes likely explain stock movements. If a YouTube release goes viral, the potential investor rally could offset some negativity.

More Breaking News

These trial revelations require investors to pause. While trials that don’t meet their primary endpoints can cause jitters, breakthroughs from subpopulations deliver hope and patient demographic insights that could shape more targeted treatments and, indeed, profits in the future.

Stock Chart Analysis

Recent trading patterns offer further intrigue. On Jul 29, 2025, the stock opened at $2.98, rising to $3.19, but pulled back to close at $3.16. This marked a slight increase from the opening. In contrast, Jul 30 witnessed a notable drop; the stock closed at $2.68, reflecting a more than 15% plummet over the preceding two-day trading.

Moreover, the July intraday trade data indicates wild fluctuations. At 8:00 am on Aug 1, 2025, prices shot up from $2.64 to $3.01. This spike points to brisk trading volumes, sparked perhaps by positive sentiment around XPro and potential hopes for promising Phase 2 results. By contrast, post-market trades by 9:18 am settled down slightly, closing at $2.92.

Interpreting the Numbers

Where do these fluctuations leave investors? Some view it as an opportunity to seize shares at a potential discount owing to these trial confusions. Other more cautious traders regard it as a harbinger for volatility, advising restraint until more definitive data unfolds.

Market strategies, therefore, hinge on investor temperament. Aggressive players may lean into XPro potential—eyes locked on forthcoming analyses. On the contrary, prudent investors may stay sidelined, assessing financial transparency and forward trajectory, perhaps hedging their bets.

Conclusion

With INmune Bio shadowboxing with medical innovation as its partner, certain opportunities stem from the allure of breakthroughs. Yet risk-averse traders must remember, while breakthroughs entice, only perpetual application assures profitability. In the world of trading, as millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” In an era defining moment for Alzheimer’s breakthroughs, how you place your chips could determine your win-loss ledger. Will INmune Bio’s narrative unfold favorably or spin you tales of caution?

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”